Publications
216
Citations
14,608
Est. group size
~13
Recurring co-author estimate
Active years
40
Publishing since 1986
Douglas W. Scharre studies dementia and related cognitive disorders, particularly Alzheimer's disease and Lewy body dementia, focusing on detection, biomarkers, and clinical management. His work combines clinical research (symptom management, clinical trials, biomarker evaluation) with computational approaches like machine learning for early detection using cognitive tests, genetic risk scores, and neuroimaging data. This research aims to improve diagnosis, monitor disease progression, and support patients and clinicians managing cognitive decline.
Publication output has grown over the past decade, rising from around 9-12 papers per year before 2020 to a peak of 28 in 2023, with continued strong activity through 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction
PubMed · 2025
- Management of Cognitive and Autonomic Symptoms in LBD
Alzheimer s & Dementia · 2024
- Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction
Scientific Reports · 2023
- Overcoming Recruitment Challenges and Increasing Representation and Diversity of Participation in Early MCI Clinical Trials: The MIND Study Experience
Alzheimer s & Dementia · 2023
- Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
Frontiers in Neurology · 2022
- Evaluation and Management of Delirium in Dementia
Current Treatment Options in Neurology · 2022
- The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice
Neurology · 2022
- Detection of cognitive impairment from eSAGE cognitive data using machine learning
Alzheimer s & Dementia · 2022
- Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
Preprints.org · 2021
- Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer’s disease diagnosis and progression monitoring
Chemical Engineering Journal · 2020
- Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
Alzheimer s Research & Therapy · 2019
- McLeod syndrome: Five new pedigrees with novel mutations
Parkinsonism & Related Disorders · 2019
- O5‐03‐04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE
Alzheimer s & Dementia · 2018
- Scientific Reports×23
- Nature Communications×17
- Neurology×14
- Alzheimer s & Dementia×10
- Figshare×8
- Liana G. Apostolova
Medicine · Indiana University
- Scott Herring
Medicine · Indiana University
- Kelley Faber
Medicine · Indiana University
- Jared R. Brosch
Medicine · Indiana University
- Scott Neu
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile